Zai Lab Limited (ZLAB) is a Biotechnology company in the Healthcare sector, currently trading at $21.96. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ZLAB = $35 (+59.4% upside).
Valuation: ZLAB trades at a trailing Price-to-Earnings (P/E) of -13.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.42.
Financials: revenue is $460M, +29.7%/yr average growth. Net income is $176M (loss), growing at +28.5%/yr. Net profit margin is -38.1% (negative). Gross margin is 58.6% (-7 pp trend).
Balance sheet: total debt is $224M against $716M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 2.45 (strong liquidity). Debt-to-assets is 19.1%. Total assets: $1.2B.
Analyst outlook: 9 / 11 analysts rate ZLAB as buy (82%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
